Ophthalmic Business News

Investing in bonds may seem boring and not sexy like buying individual stocks, but bonds help provide diversification and stability to one’s portfolio.

  The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

On this episode, Cathleen McCabe, MD, and Laura Enyedi, MD, chat with guest Cynthia Pong, JD, about combating burnout, changing up careers, ‘career insurance’ and how to negotiate your contract successfully.

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription Drug User Fee Act date of Oct. 23, according to a press release from Sydnexis.

  The FDA approved Encelto, an encapsulated cell therapy, for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

Physicians typically have tax reduction and long-term wealth accumulation at the top of their financial objectives.

The FDA granted fast track designation to phentolamine ophthalmic solution 0.75% to treat significant chronic night driving impairment in patients who have undergone keratorefractive surgery.

Editor’s note: This is a developing news story. Please check back soon for updates.

Permanent life insurance shares notable characteristics with an asset class many physicians own — real estate — particularly in the realm of tax advantages.